Application of Neuroprotective Beta Amyloid Core Peptides and Peptidomimetic Derivatives to the Treatment of Alzheimer's Disease

Technology #ua17-050

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Robert Nichols
Professor
Kelly Forest
Ph.D. Student
Victor Hruby
Regents Professor Emeritus, Chemistry & Biochemistry
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Title: Application of Neuroprotective Beta Amyloid Core Peptide and Peptidomimetic Derivatives to the Treatment of Alzheimer’s Disease

 

Invention: The present invention is a 6-peptide sequence and a peptidomimetic capable of suppressing the production of beta-amyloid and the aggregation and beta-amyloid into plaques. This technology mimics the smallest beta-amyloid peptide sequence necessary to prevent formation of beta-amyloid plaques and limit levels in the cerebrospinal fluid (CSF).

 

Background: Beta-amyloid aggregation is strongly linked with the development of Alzheimer’s disease and is cytotoxic in high concentrations. Lowering levels of beta-amyloid in the CSF as well as preventing the formation of beta-amyloid plaques can prevent Alzheimer’s disease as well as slow the progression of the disease in patients already afflicted. There are currently a number of large pharmaceutical companies focusing on the beta-amyloid pathway as a treatment for Alzheimer’s. Most drugs in the pipeline now are monoclonal antibodies, which rely on generating an immune response to lower levels of beta-amyloid in the CSF.

 

Applications:

  • Prevention and treatment of Alzheimer’s

 

Advantages:

  • Offers the smallest necessary peptide sequence
  • Preventative and therapeutic
  • Non-cytotoxic
  • Does not rely on creating an immune response

 

Licensing Manager:

Rakhi Gibbons

RakhiG@tla.arizona.edu

(520) 626-6695